Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹1 Cr
Revenue (TTM)
₹-- Cr
Net Profit (TTM)
₹0 Cr
ROE
0 %
ROCE
-7.7 %
P/E Ratio
--
P/B Ratio
-0.1
Industry P/E
--
EV/EBITDA
-141.7
Div. Yield
0 %
Debt to Equity
-1.2
Book Value
₹-22.9
EPS
₹-0.3
Face value
10
Shares outstanding
8,587,899
CFO
-10.32 Cr
EBITDA
-19.25 Cr
Net Profit
-34.89 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
BSE Commodities
| -4.9 | -8.2 | -6.3 | 5.0 | 15.1 | 11.3 | 15.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
No Review & Analysis are available.
Manufacture of organic and inorganic chemical compounds n.e.c.
Incorporated
1982
Chairman
P K Mahajan
Managing Director
P K Mahajan
Headquarters
Navi Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Since, TTM earnings of EPIC Enzymes Pharmaceuticals & Indl Chemicals Ltd is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2012
|
0.00
|
-0.08
|
|
2011
|
0.00
|
-0.11
|
|
2010
|
0.00
|
-0.43
|
|
2009
|
0.00
|
-0.34
|
|
2008
|
0.00
|
-1.25
|
The 52-week high and low of EPIC Enzymes Pharmaceuticals & Indl Chemicals Ltd are Rs -- and Rs -- as of 02-Apr-2026.
EPIC Enzymes Pharmaceuticals & Indl Chemicals Ltd has a market capitalisation of ₹ 1 Cr as on 15-Jan-2013. As per SEBI classification, it is a company.
Before investing in EPIC Enzymes Pharmaceuticals & Indl Chemicals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.